During the past decade, Umberto I Pol. di Roma-Universita di Roma La Sapienza conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 8 clinical trials were completed, i.e. on average, 114.3% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 6 clinical trials were completed. i.e. 300% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Umberto I Pol. di Roma-Universita di Roma La Sapienza" #1 sponsor was "Boehringer Ingelheim" with 4 trials, followed by "Takeda" with 2 trials sponsored, "Actelion" with 1 trials sponsored, "Alexion" with 1 trials sponsored and "Baxalta now part of Shire" with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Umberto I Pol. di Roma-Universita di Roma La Sapienza" #1 collaborator was "Baxalta Innovations GmbH, now part of Shire" with 1 trials as a collaborator and "Eli Lilly and Company" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Umberto I Pol. di Roma-Universita di Roma La Sapienza" are "Stroke" (2 trials), "Alzheimer's Disease" (1 trials), "Atrial Fibrillation" (1 trials), "Coronary Artery Disease" (1 trials) and "Erosive Esophagitis" (1 trials). Many other conditions were trialed in "Umberto I Pol. di Roma-Universita di Roma La Sapienza" in a lesser frequency.

Most popular intervention types in "Umberto I Pol. di Roma-Universita di Roma La Sapienza" are "Drug" (8 trials), "Biological" (2 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Dexlansoprazole" (2 trials), "ASA 100 mg" (1 trials), "Aducanumab (BIIB037)" (1 trials) and "Dabigatran etexilate" (1 trials). Other intervention names were less common.

The vast majority of trials in "Umberto I Pol. di Roma-Universita di Roma La Sapienza" are 11 trials for "All" genders.

Currently, there are NaN active trials in "Umberto I Pol. di Roma-Universita di Roma La Sapienza". 1 are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in Umberto I Pol. di Roma-Universita di Roma La Sapienza, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Umberto I Pol. di Roma-Universita di Roma La Sapienza, 1 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".